Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (9898)	1/11/2007 5:15:00 PM
From: Rocky9	Respond to of 10280

You didn't say anything "stoooooooopid." It's just that some of would say something very stoooooooopid if we said anything at all on the topic.

To: scaram(o)uche who wrote (9898)	1/30/2007 1:06:22 AM
From: tuck	Read Replies (1) \| Respond to of 10280

>>what, I said something stoooooooopid?? nobody has any further thoughts?<< The problem is that there is no information to speak of on this combination. I went fishing for it and got no bites. Hypnion hasn't published anything I can find about the drug aside from that PR and vague hype on their out of date website. No info on selectivity for 5-HT2A versus 5-HT2B, but the drug might be tweaked trazodone with something else spliced to it (see the app below). There may be some nuggets in the patent apps, which are much more current. However, what I've looked at is fairly cryptic (partly because there's lots of --yuck -- chemistry, and partly because much is redacted). Some answers regarding metabolites here(?): appft1.uspto.gov You're much better at sifting through patents than I am. If you care enough, because of your Arena stake, feel free to take a whack at them. Cheers, Tuck